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Abstract
Background: n-3 polyunsaturated fatty acids (n-3 PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), are thought to exert protective effects in cardiovascular diseases. In addition, n-3 PUFAs have demonstrated
anti-cancer effects in vitro and in vivo.
Objective: We investigated the anti-cancer effects and mechanism of action of EPA on PC3 prostate cancer cells in vitro.
Methods: PC3 cells were treated with various concentrations of EPA, and cell survival and the abilities of migration and
invasion were evaluated. The time course of the growth inhibitory effect of EPA on PC3 cells was also assessed.
The mechanism underlying the anti-cancer effects of EPA was investigated by human phosphokinase and human
apoptosis antibody arrays, and confirmed by western blot analysis. We also examined the contribution of reactive
oxygen species (ROS) to the effects of EPA using the ROS inhibitor N-acetyl cysteine.
Results: EPA decreased the survival of PC3 cells in a dose-dependent manner within 3 h of application, with an
effective concentration of 500 μmol/L. EPA inhibited proline-rich tyrosine kinase (Pyk)2 and extracellular signal-
regulated kinase 1/2 phosphorylation as determined by western blotting and the antibody arrays. The growth of
PC3 cells was inhibited by EPA, which was dependent on ROS induction, while EPA inhibited Pyk2
phosphorylation independent of ROS production.
Conclusions: Inhibition of Pyk2 phosphorylation and ROS production contribute to the anticancer effects of EPA
on PC3 cells.
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Introduction
Prostate cancer (PC) is the second most common cancer
in men worldwide, with the incidence increasing in
Asian countries, including Japan [1, 2]. Standard treat-
ments for PC include surgery, radiation, hormone
therapy, and chemotherapy. Advanced PC with metasta-
sis is treated with androgen deprivation therapy (ADT)
in association with medical or surgical castration [3].
However, after several years of treatment, patients ultim-
ately develop castration resistance; non-metastatic or
metastatic castration-resistant (CR) PC is refractory to
ADT and develops mechanisms to proliferate irrespect-
ive of castration. Furthermore, anti-androgen therapy
can worsen the patient’s condition by stimulating PC
growth. This has been demonstrated with flutamide
therapy and is known as anti-androgen withdrawal syn-
drome [4]. Only a few chemotherapeutics and radiation
have been developed for the treatment of CRPC [5], and
these have not improved the poor prognosis of this
disease [6].
There is growing evidence that n-3 polyunsaturated
fatty acids (n-3 PUFAs) found in fish oil—especially
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA)—can improve lipid metabolism and blood lipid
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profiles, prevent the progression of atherosclerosis, and
reduce the incidence of cardiovascular diseases [7] as
well as liver and plasma triglyceride levels [8]. We previ-
ously demonstrated that chronic oral administration of
EPA prevented endothelial dysfunction in a mouse
model of type 2 diabetes [9]. n-3 PUFAs have also been
reported to have various anti-cancer effects in several
types of malignancy in vitro and in vivo. n-3 PUFAs
inhibit extracellular signal-regulated kinase (ERK) and
Akt signaling pathways and show anti-cancer effects in
breast cancer [10], reduce the incidence of liver cancer
in hepatitis virus-infected patients [11], and lower the
risk of pancreatic cancer [12]. Cis-unsaturated fatty
acids including EPA are easily incorporated into cancer
cells and induce free radical generation, inducing
tumoricidal action [13–16]. However, other studies
have suggested that there is insufficient evidence for a
significant association between n-3 PUFAs and cancer
incidence [17].
We previously reported that EPA and DHA have
anti-proliferative, −migratory, and -invasive effects in
the PC3 CRPC cell line [18]. We also observed that
the combination of anti-cancer drugs and n-3 PUFAs
synergistically inhibited the proliferation of PC3 cells
(unpublished data). However, the mechanism of
action of n-3 PUFAs, and specifically, the molecular
basis for the inhibitory effects of EPA on PC3 cell
proliferation, migration, and invasion has yet to be
defined.
Fig. 1 Effect of EPA on PC3 cell proliferation. After 24 h of culture in
serum-free medium, various concentrations of EPA (0, 100, 300, and
500 μM) were added to the cultures. Data represent mean + SEM
(n = 3). **P < 0.01 vs. 0 μM
Fig. 2 Effect of EPA on the time course of PC3 cell proliferation. After 24 h of culture in serum-free medium, EPA (500 μM), or vehicle was added
to the cells. Data represent mean ± SEM (n = 3). **P < 0.001 vs 0 h; #P < 0.05, ##P < 0.01 v. vehicle
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Various signaling pathways control cell proliferation;
their dysregulation can lead to over-proliferation and
aberrant migration and invasion. Tyrosine kinase (TK)
is an important mediator of cell proliferation. Recep-
tor (R) TK is a transmembrane receptor with TK
activity, whereas non-receptor (NR) TK is present in
the cytoplasm and comprises Abl, Src, and proline-
rich TK (Pyk)2 families. Various NRTKs are expressed
in PC3 cells, and Src plays a role in multiple bio-
logical processes in PC cells [19]. Activation of these
TKs leads to cell proliferation through activation of
transcription factors that promote cell cycle
progression.
NRTKs enhance the proliferation of cancer cells to
promote their survival, so suppressing these pathways
can lead to cell growth inhibition or death. Most
cancer cells are resistant to apoptosis and activate
pathways that suppress the pro-apoptotic active form
of caspases [20]. Moderate ROS levels may cause
tumorigenesis through DNA damage in pro-
tumorigenic cells [21]. Thus, eliminating or reducing
ROS production is a potential strategy for cancer
therapy, since ROS also regulate the activation of sev-
eral RTKs and NRTKs [22]. On the other hand, EPA-
induced ROS overproduction stimulates apoptotic
signals in HepG2 liver cancer cells [23], and oxidative
stress causes PC3 cell death by stimulating mitochon-
drial ROS production and apoptosis [24]. DHA has
been found to cause cell death by inducing ROS pro-
duction in PC3 and DU145 PC cells [25].
In the present study, we investigated the mechanism
underlying the anti-cancer effects of n-3 PUFA EPA, first
by characterizing the optimal concentration and time
required for these effects in PC3 cells, and then by
analyzing protein expression by western blotting and
antibody arrays. To clarify the effects of ROS production




EPA (Sigma-Aldrich, St. Louis, MO, USA) was dis-
solved in 99% isopropanol (Wako, Tokyo, Japan) and
stored at − 30 °C. For experiments, EPA was dissolved
in serum-free Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, New York, NY, USA) containing 3%
bovine serum albumin (BSA) (Sigma-Aldrich), and
NAC (Wako) was dissolved in phosphate-buffered
saline (PBS). Human phospho-kinase array (R&D
Systems, Minnesota, MN, USA) and the human apop-
tosis antibody Array Membranes (Abcam, Cambridge,
UK) were used for protein analysis. Antibodies against
ERK1/2, phosphorylated (p)-ERK1/2, Pyk2, p-Pyk2,
and β-actin were from Cell Signaling Technology
Japan (Tokyo, Japan) and were diluted with Can Get
Signal reagent (Toyobo, Osaka, Japan).
Cell culture
PC3 cells (Riken BRC Cell Bank, Tsukuba, Japan) were
grown in DMEM (Gibco) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 U/mL of
penicillin, and 100 μg/mL of streptomycin (Gibco). The
cells were cultured at 37 °C in a humidified 5% CO2
atmosphere.
Fig. 3 Effect of EPA on EPA on PC3 (a) cell migration and (b)
invasion. Double-chambered cell culture dishes with a transwell
insert separating the two chambers were used to evaluate PC3
cell migration and invasion. Cells were seeded in the upper
chamber, which was uncoated (migration) or coated (invasion)
with Matrigel, while the lower chamber was filled with DMEM
containing 10% FBS. Data represent mean + SEM
(n = 3). *P < 0.05
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Cell proliferation assay
PC3 cells were seeded in 35-mm dishes at a density of
3 × 105 cells/dish in DMEM containing 10% FBS and
incubated for 24 h, and the culture medium was replaced
with serum-free DMEM after washing with PBS. After
an additional 24 h, the cells were washed with PBS, and
serum-free medium containing 3% BSA and various
concentrations of EPA (100–500 μM) were added. After
24 h, the number of cells was counted with a
hemocytometer.
Time course of cell proliferation
PC3 cells were seeded in a 35-mm high μ-Dish Grid-
500 (Ibidi, Planegg, Germany) at a density of 3 × 105
cells/dish in DMEM containing 10% FBS. After 24 h,
the cells were washed with PBS, and serum-free
DMEM was added; after another 24 h, the cells were
washed with PBS, and serum-free medium containing
3% BSA with or without EPA (500 μM) was added.
Cells were imaged with a microscope and counted at
the indicated times.
Migration and invasion assay
Migration and invasion were assessed as described in our
previous study [18]. Briefly, we used Transwell mem-
branes (8-μm pore size; Corning Inc., Corning, NY, USA)
with or without Matrigel coating. PC3 cells were cultured
in the upper chamber of a Transwell insert in serum-free
medium containing various concentrations of EPA. The
lower chamber was filled with DMEM containing 10%
FBS. For the migration assay, Matrigel-uncoated upper
chambers were used; cells were seeded at a density of 2 ×
105 cells/mL, and after 24 h, the number of cells that had
migrated into the lower chamber was counted. For the in-
vasion assay, Matrigel-coated upper chambers were used.
Before seeding the cells, Matrigel was fixed by incubation
for 90min, and cells were seeded at a density of 1 × 105
cells/mL. After 48 h, cells that had invaded into the lower
chamber were counted.
Antibody arrays
PC3 cells were cultured in DMEM containing 10%
FBS for 24 h, then cultured in serum-free medium for
Fig. 4 Results of the apoptosis antibody array. PC3 cells with or without EPA treatment were analyzed. The y axis shows the pixel density (%). The
expression level of each protein in the control was adjusted to 100%
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an additional 24 h before treatment with EPA
(500 μM) or vehicle as a control. After 2 h of incuba-
tion with EPA or vehicle, samples were prepared for
the antibody array according to the manufacturers’
protocols. Chemiluminescence detection was per-
formed on a Lumi Cube (Liponics, Tokyo, Japan)
using Clarity Western ECL Substrate (Bio-Rad,
Hercules, CA, USA). Images of the arrays were ana-
lyzed using Image J software (National Institutes of
Health, Bethesda, MD, USA).
Inhibition of ROS production
PC3 cells were cultured in a 35-mm dish at a density
of 3 × 105 cells/dish in DMEM containing 10% FBS
for 24 h, and then washed with PBS and incubated in
serum-free DMEM for an additional 24 h. The cells
were washed with PBS, and EPA (500 μM) with or
without 5 mM of NAC (Wako) was added, cells were
incubated for 24 h, and cell numbers were counted
with a hemocytometer.
Western blot analysis
PC3 cells were cultured in 60-mm dishes at a density
of 8 × 105 cells/dish in 10% FBS-containing DMEM
for 24 h. PC3 cells were cultured with serum starva-
tion for an additional 24 h, then treated with EPA
(500 μM) or vehicle. The cells were lysed in M-PER
(Thermo Fisher Scientific, Waltham, MA, USA) and
centrifuged at 13,000 rpm (30,250 g) at 4 °C for 10
min. Protein samples were diluted in 2× Laemmli
sample buffer (Bio-Rad), then boiled at 100 °C, and
20 μg of protein were loaded in each lane of a TGX
precast gel (Bio-Rad) and resolved by electrophoresis
(100 V, 0.3 A). The proteins were transferred to an
Immun-Blot polyvinylidene difluoride membrane (Bio-
Rad) at 100 V and 0.3 A for 1 h. The membrane was
blocked with Block Ace (KAC, Kyoto, Japan) for 1 h
Fig. 5 Results of two experiments using the human phosphokinase array. The y axis shows pixel density (%). For the control groups in
experiments 1 and 2 (Expt1 Control and Expt2 Control, respectively), the expression level of each protein was adjusted to 100%. For the EPA-
treated groups in experiments 1 and 2 (Expt1 EPA and Expt2 EPA, respectively), the expression level of each protein was determined relative to
that in the corresponding control group
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and probed with antibody solution for 1 h at room
temperature. The membrane was washed with Tris-
buffered saline (Bio-Rad) containing 1% Tween 20.
Lumi Cube and Clarity Western ECL substrate were
used for signal detection, and protein band intensity
was analyzed using Image J software.
Statistical analysis
Statistical analyses were performed using R v.3.4.3
(https://www.r-project.org/). Data are presented as
means ± standard error, and differences between means
were evaluated with Dunnett’s test. A P value less than
0.05 was considered statistically significant.
Results
EPA suppresses PC3 cell proliferation
EPA inhibited the proliferation of PC3 cells in a dose-
dependent manner (Fig. 1). However, only the highest
concentration of EPA (500 μM) significantly reduced the
number of cells to 50% of the control value.
In serum-free medium, the number of PC3 cells in the
control group did not change over a 24-h period, but
gradually decreased with EPA treatment, with significant
differences detected after 3 h. After 12 h, the number of
cells was 50% of the control value and remained con-
stant up to 24 h (Fig. 2).
EPA inhibits PC3 cell migration and invasion
EPA inhibited both PC3 cell migration and invasion in a
dose-dependent manner, and the rate of migration and
invasion relative to the control was 43% (Fig. 3a) and
26% (Fig. 3b), respectively, at 200 μmol/L EPA. Thus,
PC3 cell invasion was inhibited to a greater extent than
migration by EPA.
Proteins associated with phosphokinase and apoptosis
pathways are activated by EPA treatment
Using two types of antibody arrays, we determined that
proteins involved in the phosphokinase and apoptosis
pathways were activated by EPA treatment. Based on
the results shown in Fig. 2, protein samples for anti-
body arrays and western blotting were prepared 2 h
after adding 500 μmol/L EPA. More significant results
were obtained between the EPA-treated and untreated
Table 1 Difference in expression levels of various proteins
relative to the control in PC3 cells treated with EPA
1, 2. Differences relative to the control are shown as ± > 20%
Table 2 Differences in the expression levels of various proteins
in EPA-treated PC3 cells relative to the control (related to Fig. 5)
1. Differences relative to the control are shown as ± ± ± ± > 20%
2. Differences relative to the control are shown as ± ± ± > 10%
3. Differences relative to the control are shown as ± ± > 5%
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control groups using the phosphokinase as compared
to the apoptosis array (Figs. 4 and 5). The expression of
apoptosis-related proteins including soluble tumor ne-
crosis factor receptor (sTNF-R)2, second mitochondria-
derived activators of caspase (SMAC), Survivin, tumor
necrosis factor related apoptosis-inducing ligand recep-
tor (TRAIL-R)1, caspase 8, B-cell lymphoma (Bcl)-2,
and p53 differed by more than 20% between the two
groups (Table 1), with sTNF-R2 and Bcl-2 being down-
regulated and the other proteins being upregulated by
EPA treatment.
The phosphokinase array data showed increased or
decreased phosphorylation of several kinases (Fig. 5 and
Table 2). EPA reduced the phosphorylation of several
proteins by over 20% relative to the control, including
Pyk2, endothelial nitric oxide synthase (eNOS), c-Jun,
and ribosomal S6 kinases (RSK)1/2/3.
Contribution of ROS to PC3 cell death
We next analyzed the contribution of ROS to the
effects of EPA on PC3 cell survival and found that
EPA treatment decreased survival to 60% of the
control rate, whereas NAC (5 mmol/L) had no effect.
Treatment with both EPA and NAC restored the
survival rate to the control level. Thus, NAC abro-
gates the anti-cancer effect of EPA against PC3 cells
(Fig. 6).
EPA inhibits ERK and Pyk2 phosphorylation
To confirm the mechanism of action of EPA, cells were
treated at a concentration of 500 μmol/L, and the
expression of native and phosphorylated ERK and Pyk2
was examined by western blotting. EPA significantly
suppressed ERK phosphorylation at 1 and 2 h, although
there was no difference relative to the control group
after 3 h (Fig. 7). A similar significant inhibitory effect
was observed on Pyk2 phosphorylation at 2 and 4 h
(Fig. 8). Treatment with the ROS inhibitor NAC (5 mM)
alone did not affect Pyk2 phosphorylation, while NAC
slightly enhanced the inhibitory effect of EPA on Pyk2
phosphorylation (Fig. 9).
Discussion
The anti-cancer effects of n-3 PUFAs in vitro and
in vivo are well known [13, 14, 18, 26–31], and these
effects have been observed in PC cells. Our previous
study showed that the n-3 PUFAs EPA and DHA inhibit
PC3 cell proliferation, migration, and invasion [18].
Several reports have indicated that n-3 PUFAs-
induced apoptosis or oxidative stress suppresses the
growth of various types of cancer cells, including PC
cells [32, 33]. Activation of NRTKs may be related to
PC cell growth, and clinical trials of therapeutics that
target NRTK are currently underway [34, 35]. Other
mechanisms of action have been proposed for the
anti-cancer effects of n-3 PUFAs [36, 37]. In this
study, we addressed this question using phosphoki-
nase and apoptosis antibody arrays and examined the
contribution of ROS to the anti-cancer effect of EPA
on PC3 cells.
For the antibody array analysis, the cell cycle of PC3
cells was synchronized by culturing in serum-free
medium for 24 h. PC3 cells are relatively resistant to the
anti-cancer effects of EPA. We treated cells with a
moderately high concentration of EPA that was none-
theless within the physiological range (500 μM). PC3
cell proliferation did not change over 24 h in the
control group, which is consistent with the notion
that the rates of proliferation and death are equiva-
lent in PC3 cells grown under conditions of moderate
nutrient starvation. In contrast, the number of cells in
the EPA-treated group decreased over time, with
significant differences relative to the control group
observed from 3 h to 24 h.
The results of the apoptosis array showed that EPA
increased the expression of the pro-apoptotic proteins
TRAIL-R1, caspase 8, and p53, and decreased that of
the anti-apoptotic protein Bcl-2. However, EPA also
increased the levels of the anti-apoptotic proteins
SMAC and Survivin while having no effect on caspase
3. We speculated that ROS induced cell death via a
pathway independent of caspase-induced apoptosis.
Fig. 6 Effect of NAC on the anti-cancer effect of EPA against PC3
cells. After 24 h of culture in serum-free medium, cells were treated
with EPA (500 μM) or NAC or both. Data represent mean + SEM
(n = 3). *P < 0.05
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To test this hypothesis, we evaluated the effect of the
ROS inhibitor NAC on EPA-treated cells. First, we
measured ROS generation at two time points, 2 and
24 h. In these experiments, we observed relevant (not
significant) ROS generation induced by EPA only at
2 h, and NAC reduced the ROS level to the control
(data not shown). We observed that the addition of
NAC abrogated the anti-cancer effects of EPA (Fig. 6),
suggesting that ROS induced by EPA suppressed PC3
cell proliferation. This is supported by previous re-
ports showing that the anti-cancer effects of n-3
PUFAs are mediated by ROS in liver cancer and PC
cells [23, 24].
We also investigated the contribution of cell prolif-
eration pathways to the anti-cancer effects of EPA
using a phosphokinase antibody array. The results
showed that Pyk2, eNOS, c-Jun, and RSK1/2/3 were
downregulated by over 20% by EPA treatment as
compared to the control group. Western blot analysis
revealed that ERK and Pyk2 phosphorylation were
inhibited by EPA (Figs. 7 and 8). Suppressing ROS
production with NAC did not affect the inhibitory ef-
fects of EPA on Pyk2 phosphorylation, suggesting that
the suppression of Pyk2 phosphorylation by EPA does
not involve modulation of ROS. Pyk2 is a member of
the focal adhesion kinase (FAK) family of NRTK and
plays important roles in cell survival, proliferation,
and migration [38–41]. In our experiments, FAK
phosphorylation was also suppressed by EPA treat-
ment (Table 2). FAK is localized at the site of cell
adhesion with the extracellular matrix along with
integrins, whereas Pyk2 associates with integrin within
Fig. 7 Effect of EPA on ERK1/2 phosphorylation. Upper panel: Representative results of western blot analysis. Lower panel: Pixel density of the
control group at the indicated times was adjust to 100%; relative pixel density of EPA-treated PC3 cells is shown. Data represent mean + SEM
(n = 3). *P < 0.05
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the cell [42, 43]. Since several types of integrins are
expressed in PC3 cells and interact with extracellular
matrix, inhibition of activated FAK at these sites may
prevent cell adhesion and migration [44]. The N-
terminal domain of FAK has phosphorylation sites for
the cell proliferation-related factors epidermal growth
factor receptor, c-Met, and Src [45]. The antibody
used in the antibody array detected phosphorylated
tyrosine 402 of Pyk2, which is necessary for Src acti-
vation [40] and was slightly reduced in our experi-
ment (Table 2). It was reported that Pyk2 activation
induced smooth muscle contraction by activating
Rho-associated kinase signaling [46], and FAK and
Pyk2 show similar activities on this pathway in the
regulation of cell migration [38, 47, 48]. Activation of
both factors leads to abnormalities in cell morphology
and movement associated with malignant transformation.
Our results suggest that EPA negatively regulates the
proliferation, migration, and invasion of PC3 cells via
inhibition of Pyk2 and FAK [18].
Pyk2 is an NRTK that is activated by increased intra-
cellular Ca2+ concentrations [49, 50], which are in
turn increased by n-3 PUFAs and ROS [23, 51–53].
In our results, the n-3 PUFA EPA inhibited Pyk2
phosphorylation, whereas ROS inhibition by NAC did
not affect the inhibitory effects of EPA, suggesting
that EPA blocks Pyk2 activation independent of intra-
cellular Ca2+ levels.
Fig. 8 Effect of EPA on Pyk2 phosphorylation. Upper panel: Representative result of western blot analysis. Lower panel: Pixel density of the
control group at the indicated times was adjusted to 100%; relative pixel density of EPA-treated PC3 cells is shown. Data represent mean + SEM
(n = 3). *P < 0.05
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Conclusions
Our results demonstrate that EPA induced cell death by
stimulating ROS production in PC3 cells, and sup-
pressed Pyk2 phosphorylation inducing inhibition of cell
proliferation, migration, and invasion partly controlled
by downstream Pyk2 signaling. Our findings were
summarized in Fig. 10. These results provide a basis for
the development of novel therapeutics for the treatment
of PC.
Abbreviations
ADT: Androgen deprivation therapy; Bcl-2: B-cell lymphoma 2;
CRPC: Castration-resistant prostate cancer; DHA: Docosahexaenoic acid;
eNOS: Endothelial nitric oxide synthase; EPA: Eicosapentaenoic acid;
ERK: Extracellular signal-regulated kinase; FAK: Focal adhesion kinase; n-3
PUFA: n-3 polyunsaturated fatty acid; NAC: N-acetyl cysteine; NRTK: Non-
receptor tyrosine kinase; PBS: Phosphate-buffered saline; PC: Prostate cancer;
Pyk2: Proline-rich tyrosine kinase-2; ROS: Reactive oxygen species; RSK1/2/
3: Ribosomal S6 kinase 1/2/3; RTK: Receptor tyrosine kinase; SMAC: Second
mitochondria-derived activators of caspase; sTNF-R2: Soluble tumor necrosis
factor receptor 2; TRAIL-R1: Tumor necrosis factor-related apoptosis-inducing
ligand and receptor 1
Acknowledgments
We would like to thank FORTE (https://www.forte-science.co.jp/) for their
language review of the manuscript.
Adherence to national and international regulations
Not applicable.
Authors’ contributions
KO conceived and designed the study. KO performed the experiments. SS
performed several experiments according to the reviewer’s comments. KO,
CW and KK wrote the paper. KO, TS, KO and SS designed the figures and
tables. KO, CW, TS and KK reviewed and edited the manuscript. All authors
read and approved the manuscript and agree to be accountable for all
aspects of the research in ensuring that the accuracy or integrity of any part
of the work are appropriately investigated and resolved.
Funding
This work was partly supported by JSPS KAKENHI (Grant Number:
JP26350904).
Availability of data and materials
Available.





The authors declare that they have no competing interests.
Author details
1Laboratory of Physiology, Faculty of Pharmaceutical Sciences, Josai
University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan. 2Laboratory of
Clinical Pathology, Faculty of Pharmaceutical Sciences, Josai University, 1-1
Keyakidai, Sakado, Saitama 350-0295, Japan.
Received: 14 May 2019 Accepted: 30 September 2019
References
1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju
TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman
N, Amini E, et al. Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and disability-adjusted life-years
for 29 cancer groups, 1990 to 2016: a systematic analysis for the global
burden of disease study. JAMA Oncol. 2018;4(11):1553–68.
2. Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J
Urol. 2018;25(6):524–31.
3. Ritch C, Cookson M. Recent trends in the management of advanced
prostate cancer. F1000Res. 2018;21:7.
4. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a
large cohort of unselected patients with advanced prostate cancer. Cancer.
1995;76(8):1428–34.
5. Hurwitz MD. Chemotherapy and radiation for prostate cancer. Transl Androl
Urol. 2018;7(3):390–8.
Fig. 9 NAC enhances the inhibition effect of EPA on Pyk2
phosphorylation. After 24 h of culture in serum-free mediumm, PC3
cells were treated with EPA (500 μM) or NAC or both. Data represent
mean + SEM (n + 3). *P < 005
Fig. 10 EPA-induce anti- cancer signaling in PC3 cells
Oono et al. Lipids in Health and Disease           (2020) 19:15 Page 10 of 12
6. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreia U, Ivashchenko P,
Demirthan E, Modelska K, Phung D, et al. Enzalutamide in men with
nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;
378(26):2465–74.
7. Balk EM, Lichtenstein AH. Omega-3 fatty acids and cardiovascular disease:
summary of the 2016 agency of healthcare research and quality evidence
review. Nutrients. 2017;9(8). https://doi.org/10.3390/nu9080865.
8. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans:
a critical review. J Lipid Res. 1989;30(6):785–807.
9. Takenouchi Y, Ohtake K, Nobe K, Kasono K. Eicosapentaenoic acid ethyl
ester improves endothelial dysfunction in type 2 diabetic mice. Lipids
Health Dis. 2018;17(1):118.
10. Serini S, Calviello G. Modulation of Ras/ERK and phosphoinositide signaling
by long-chain n-3 PUFA in breast cancer and their potential complementary
role in combination with targeted drugs. Nutrients. 2017;9(3). https://doi.
org/10.3390/nu9030185.
11. Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takachi R,
Tanaka Y, Mizokami M, Tsugane S, et al. Consumption of n-3 fatty acids and
fish reduces risk of hepatocellular carcinoma. Gastroenterology. 2012;142(7):
1468–75.
12. Hidaka A, Shimazu T, Sawada N, Yamaji T, Iwasaki M, Sasazuki S, Inoue M,
Tsugane S. Japan public health center-based prospective study group. Fish,
n-3 PUFA consumption, and pancreatic cancer risk in Japanese: a large,
population-based, prospective cohort study. Am J Clin Nutr. 2015;102(6):
1490–7.
13. Das UN. Tumoricidal action of cis-unsaturated fatty acids and their
relationship to free radicals and lipid peroxidation. Cancer Lett. 1991;56(3):
235–43.
14. Bégin ME, Das UN, Ells G, Horrobin DF. Selective killing of human cancer
cells by polyunsaturated fatty acids. Prostaglandins Leukot Med. 1985;19(2):
177–86.
15. Das UN, Begin ME, Ells G, Huang YS, Horrobin DF. Polyunsaturated fatty
acids augment free radical generation in tumor cells in vitro. Biochem
Biophys Res Commun. 1987;145(1):15–24.
16. Das UN, Huang YS, Begin ME, Ells G, Horrobin DF. Uptake and distribution
of cis-unsaturated fatty acids and their effect on free radical generation in
normal and tumor cells in vitro. Free Radic Biol Med. 1987;3(1):9–14.
17. MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM, Suttorp MJ, Lim
YW, Traina SB, Hilton L, Garland R, et al. Effects of omega-3 fatty acids on
cancer risk: a systematic review. JAMA. 2006;295(4):403–15.
18. Oono K, Takahashi K, Sukehara S, Kurosawa H, Matsumura T, Taniguchi S,
Ohta S. Inhibition of PC3 human prostate cancer cell proliferation, invasion
and migration by eicosapentaenoic acid and docosahexaenoic acid. Mol
Clin Oncol. 2017;7(2):217–20.
19. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate
cancer. Neoplasia. 2007;9(2):90–100.
20. Watson RW, Fitzpatrick JM. Targeting apoptosis in prostate cancer: focus on
caspases and inhibitors of apoptosis proteins. BJU Int. 2005;96(Suppl 2):30–4.
21. Moloney JN, Cotter TG. ROS signaling in the biology of cancer. Semin Cell
Dev Biol. 2018;80:50–64.
22. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J
Physiol Lung Cell Mol Physiol. 2000;279(6):1005–28.
23. Zhang Y, Han L, Qi W, Cheng D, Ma X, Hou L, Cao X, Wang C.
Eicosapentaenoic acid (EPA) induced apoptosis in HepG2 cells through
ROS-Ca2+-JNK mitochondrial pathways. Biochem Biophys Res Commun.
2015;456(4):926–32.
24. Ding Y, Ren K, Dong H, Song F, Chen J, Guo Y, Liu Y, Tao W, Zhang Y.
Flavonoids from persimmon (Diospyros kaki L.) leaves inhibit proliferation
and induce apoptosis in PC-3 cells by activation of oxidative stress and
mitochondrial apoptosis. Chem Biol Interact. 2017;275:210–7.
25. Shin S, Jing K, Jeong S, Kim N, Song KS, Heo JY, Park JH, Seo KS, Han J, Park
JI, et al. The omega-3 polyunsaturated fatty acid DHA induces simultaneous
apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR
signaling in prostate cancer cells expressing mutant p53. Biomed Res Int.
2013;2013:568671.
26. Bégin ME, Ells G, Das UN, Horrobin DF. Differential killing of human
carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids.
J Natl Cancer Inst. 1986;77(5):1053–62.
27. Corsetto PA, Montorfano G, Zava S, Jovenitti IE, Cremona A, Berra B, Rizzo
AM. Effects of n-3 PUFAs on breast cancer cells through their incorporation
in plasma membrane. Lipids Health Dis. 2011;10:73–89.
28. McEntee MF, Ziegler C, Reel D, Tomer K, Shoieb A, Ray M, Li X, Neilsen N,
Lih FB, O’Rourke D, et al. Dietary n-3 polyunsaturated fatty acids enhance
hormone ablation therapy in androgen therapy in androgen-dependent
prostate cancer. Am J Pathol. 2008;173(1):229–41.
29. Altenburg JD, Siddiqui RA. Omega-3 polyunsaturated fatty acids down-
modulate CXCR4 expression and function in MDA-MB-231 breast cancer
cells. Mol Cancer Res. 2009;7(7):1013–20.
30. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by
omega-3 fatty acids. Cancer Lett. 2008;269(2):363–77.
31. Davidson LA, Nguyen DV, Hokanson RM, Callaway ES, Isett RB, Turner ND,
Dougherty ER, Wang N, Lupton JR, Carroll RJ, et al. Chemopreventive n-3
polyunsaturated fatty acids reprogram genetic signatures during colon cancer
initiation and progression in the rat. Cancer Res. 2004;64(18):6797–804.
32. Song EA, Kim H. Docosahexaenoic acid induces oxidative DNA damage and
apoptosis, and enhances the chemosensitivity of cancer cells. Int J Mol Sci.
2016;17(8). https://doi.org/10.3390/ijms17081257.
33. Camargo CQ, Brunetta HS, Nunes EA. Effects of cotreatment with omega-3
polyunsaturated fatty acids and anticancer agents on oxidative stress
parameters: a systematic review of in vitro, animal, and human studies. Nutr
Rev. 2018;76(10):765–77.
34. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J
Pharmacol Exp Ther. 2005;315(3):971–9.
35. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding
G, McCaffrey J, Serrano SV, Matveev VB, et al. Docetaxel and dasatinib
or placebo in men with metastatic castration-resistant prostate cancer
(READY): a randomized, double-blind phase 3 trial. Lancet Oncol. 2013;
14(13):1307–16.
36. D’Eliseo D, Velotti F. Omega-3 fatty acids and cancer cell cytotoxicity:
implications for multi-targeted cancer therapy. J Clin Med. 2016;5(2). https://
doi.org/10.3390/jcm5020015.
37. Menedez JA, Lupu R. Fatty acid synthase and the lipogenetic phenotype in
cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–77.
38. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated
cellular signaling. Call Signal. 2000;12(3):123–33.
39. Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, Lo CM, Poon RT, Fan ST.
Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness
of hepatocellular carcinoma cells through c-Src/ERK activation.
Carcinogenesis. 2008;29(11):2096–105.
40. Zhao M, Finlay D, Zharkikh I, Vuori K. Novel role of Src in priming Pyk2
phosphorylation. PLoS One. 2016;11(2):e0149231.
41. Perez J, Torres RA, Rocic P, Cismowski MJ, Weber DS, Darley-Usmar VM,
Lucchesi PA. PYK2 signaling is required for PDGF-dependent vascular
smooth muscle cell proliferation. Am J Physiol Cell Physiol. 2011;301(1):
C242–51.
42. Matsuya M, Sasaki H, Aoto H, Mitaka T, Nagura K, Ohba T, Ishino M,
Takahashi S, Suzuki R, Sasaki T. Cell adhesion kinase beta forms a complex
with a new member, hic-, of proteins localized at focal adhesions. J Biol
Chem. 1998;273(2):1003–14.
43. Murphy JM, Park H, Lim STS. FAK and Pyk2 in disease. Front Biol. 2016;
11(1):1–9.
44. Juan-Rivera MC, Martinez-Ferrer M. Integrin inhibitors in prostate cancer.
Cancers (Basel). 2018;10(2). https://doi.org/10.3390/cancers10020044.
45. Lee BY, Trimpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as
a target for therapeutics. Pharmacol Ther. 2015;146:132–49.
46. Mills RD, Mita M, Walsh MP. A role for the Ca2+-dependent tyrosine kinase
Pyk2 in tonic depolarization-induced vascular smooth muscle contraction. J
Muscle Res Cell Motil. 2015;36(6):479–89.
47. Miller NL, Kleinschmidt EG, Schlaepfer DD. Rho GEFs in cell motility: novel
links between Rgnef and focal adhesion kinase. Curr Mol Med. 2014;14(2):
221–34.
48. Tornin J, Hermida-Prado F, Padda RS, Gonzalez MV, Alvarez-Fernandez C,
Rey V, Martinez-Cruzado L, Estuinan O, Menendez ST, Fernandez-Nevado L,
et al. FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC/
FAKRHO/ROCK-dependent pathway. Neoplasia. 2018;20(1):44–56.
49. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled
receptors. J Cell Physiol. 2007;213(3):589–602.
50. Hirschler-Laszkiewica I, Chen SJ, Bao L, Wang J, Zhang XQ, Shanmughapriya
S, Keefer K, Madesh M, Cheung JY, Miller BA. The human ion channel
TRPM2 modulates neuroblastoma cell survival and mitochondrial function
through Pyk2, CREB, and MCU activation. Am J Physiol Cell Physiol. 2018;
315(4):C571–86.
Oono et al. Lipids in Health and Disease           (2020) 19:15 Page 11 of 12
51. Jakobsen CH, Størvold GL, Bremseth H, Follestad T, Sand K, Mack M, Olsen
KS, Lundemo AG, Iversen JG, Krokan HE, et al. DHA induces ER stress and
growth arrest in human colon cancer cells: associations with cholesterol
and calcium homeostasis. J Lipid Res. 2008;49(10):2089–100.
52. Hempel N, Trebak M. Crosstalk between calcium and reactive oxygen
species signaling in cancer. Cell Calcium. 2017;63:70–96.
53. Yamamoto S, Shimazu S, Kiyonaka S, Takahashi N, Wajima T, Hara Y, Negoro
T, Hiroi T, Kiuchi Y, Okada T, et al. TRPM2-mediated Ca2+ influx induces
chemokine production in monocytes that aggravates inflammatory
neutrophil infiltration. Nat Med. 2008;14(7):738.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Oono et al. Lipids in Health and Disease           (2020) 19:15 Page 12 of 12
